Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Exclusion Criteria

• •Prior chemotherapy, investigational therapy or radiotherapy within 3 weeks of study entry
• •Prior autologous or allogeneic stem cell transplantation within 3 months of study entry
• •History of severe hypersensitivity or anaphylaxis to prior rituximab
• •Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, brain metastasis, or psychiatric illness that would limit compliance with study requirements
• •Pregnant women